Quarterly Member Update
May 11, 2016


CEO Roundtable on Cancer


President George H. W. Bush, Founder  
Robert A. Bradway, Chairman  |  Dr. Martin J. Murphy, CEO

A Message from the CEO

The progress of our CEO Roundtable on Cancer continues, with 2016 off to a promising start. Our CEO Roundtable’s focus on cancer prevention and research innovation provides unique opportunities to continue our bold and venturesome mission on behalf of the cancer patients whom we serve.

This is truly an exciting and hopeful time for cancer research and innovation. The CEO Roundtable on Cancer was honored to join fellow CEO Roundtable Member, Dr. Eugene Washington, Chancellor of Duke Medicine, and Dr. Michael Kastan, Duke Cancer Center Director, as they hosted a roundtable discussion with Vice President Joe Biden in support of the National Cancer Moonshot initiative. It was an honor for me, as President George H.W. Bush’s envoy, to pin the CEO Cancer Gold Standard insignia on the Vice President’s lapel … that he then proudly wore for the duration of his Duke visit. There are multiple intersections between the Vice President’s commitment and the strengths of the CEO Roundtable. Indeed, these were highlighted in recent correspondence between President Bush and his long-time friend, the Vice President.

This year, we celebrate the 15th anniversary of the CEO Roundtable and the 10th anniversary of our flagship initiative, the CEO Cancer Gold Standardâ„¢. Our Gold Standard community enables us to share the benefits of this wellness and prevention model outside the U.S., beginning with our current work in China, where the CEO Roundtable on Cancer-China was registered on December 9, 2015, as a first-of-its-kind NGO.

I am particularly pleased to recognize the progress of the Life Sciences Consortium’s independent Project Data Sphere® initiative. Building on the achievements of 2015, data providers continue to broaden the range of data sets available through this innovative research library-laboratory. Since the start of 2016, the Project Data Sphere initiative has been progressing toward its goal to receive clinical trial data for 100,000 patient lives. The goal is ambitious but we are already seeing results due to the deep commitment that our Life Sciences Consortium Members have made to data-transparency and the promise that will be realized through data-sharing.

Given the ambitious goals we have set for ourselves, we look forward to the benefits our CEO Roundtable will gain from new and renewed participation, collaboration and leadership.


We welcome our newest Members, whose contributions will no doubt enable and inspire us to continue our work on behalf of those confronting the realities of cancer.

In the past few months, our CEO Roundtable, Gold Standard and Life Sciences Consortium websites have undergone a refresh process to enhance each site’s design, navigation and content. I encourage you to visit the updated sites, and please refer others to the sites to learn more about the CEO Roundtable and its programs.

Lastly, please save the date for CEO Roundtable-XV, being held November 3-4, in Cary, N.C. As in recent years, our annual meeting will be held on the SAS Campus. Our chairman, Robert A. Bradway, will begin the meeting during dinner at The Umstead Hotel on Thursday, November 3. CEO Roundtable-XV will then be chaired by Bob on Friday, November 4, at the SAS Executive Briefing Center.

Thank you for your commitment to advancing cancer research. Together we will work on behalf of cancer patients and all those who look to us for a renewal of life’s elixir: hope.

With only my choicest regards, I am

Yours,


Martin J. Murphy, DMedSc, PhD, FASCO
Chief Executive Officer
CEO Roundtable on Cancer

 


CEO Cancer Gold Standard

Celebrating the Gold Standard 10-Year Anniversary!
Since its inception in 2006, the Gold Standard has been embraced by nearly 200 accredited employers and through them it benefits more than 5 million employees and family members worldwide. 
The success of this program began and continues with the leadership of its six inaugural employers, who have all maintained their accreditations: the American Cancer Society, Astellas, AstraZeneca, GSK, Johnson & Johnson and Novartis.

These six organizations have demonstrated a commitment to their employees’ health, year after year, taking advantage of a unique opportunity to positively impact the lives of so many. They led the way for what is now a diverse community of employers in terms of size and industry. We thank them for their commitment and hold them up as an example of leadership at its golden best!

In the past decade, we have seen the development of innovative new cancer therapies, the discovery of new evidence that has shaped screening practices, and the approval of the first cancer prevention vaccine, all of which help improve and save lives. During this time, the Gold Standard Task Force has continuously reviewed and refined its Five Pillars to ensure the requirements for accreditation are evidence-based, comprehensive and timely, and aligned with the progress made in cancer prevention and care. We are grateful to the Gold Standard Task Force, all of whom are volunteer participants from Gold Standard accredited Member companies contributing time and knowledge to establish and maintain this program’s high standards. 


Presentation to Global Business Group on Health
 
Dr. Fikry Isaac, CEO Cancer Gold Standard Task Force Co-Chair, and a member of the Global Business Group on Health (GBGH), was invited to introduce the CEO Cancer Gold Standard and its Global accreditation requirements at the February 2016 meeting of the GBGH in New York City. The group of distinguished global employers was interested in the specific requirements of Global accreditation and what “lessons learned” may be available from the four existing Global Gold Standard employers: Celgene, Helsinn, Johnson & Johnson and Novartis. Although the requirements of Global accreditation are rigorous, several GBGH members have since expressed interest in attaining accreditation.

Gold Standard Task Force Meeting 
The Gold Standard Task Force meeting is being hosted by the MD Anderson Cancer Center in Houston, TX, May 11-12. The Task Force will address an ambitious agenda to continue to update the Gold Standard requirements as the program strives to keep pace with advances in cancer screening and prevention. Look for a summary of the results from this important meeting soon. 
 
Employers Recently Earning Gold Standard Accreditation
  • Foundation Medicine, Michael Pellini, MD, Chief Executive Officer
  • Hatteras Venture Partners, Clay Thorpe, General Partner
  • Helsinn Healthcare SA, Riccardo Braglia, PhD, Group Chief Executive Officer
  • Hendrick Medical Center, Tim Lancaster, President and Chief Executive Officer
  • Pratt & Whitney, Paul R. Adams, President
  • ProMedica, Randy Oostra, DM, FACHE, President and Chief Executive Officer
  • Texas Tech University Health Sciences Center, Tedd L. Mitchell, MD, President
  • The Ohio State University, Michael V. Drake, MD, President
  • U.S. Chamber of Commerce, Thomas J. Donohue, President and Chief Executive Officer
  • White Plains Hospital, Susan Fox, President and Chief Executive Officer

Life Sciences Consortium
As the Project Data Sphere® initiative continues to grow, we are increasingly focused on demonstrating the power of the data it contains. As such, LSC-PDS Symposium-II was held on May 3, in Bethesda, MD, convened by LSC Co-Chairman, Dr. Mace Rothenberg of Pfizer and Dr. Martin Murphy. This was the second of important dialogues to enhance our collaboration that will drive innovation and better serve cancer patients. We were grateful to be joined by Dr. Richard Pazdur, Director, Office of Oncology and Hematology Products, FDA, and Dr. Douglas Lowy, Acting Director of the National Cancer Institute, and a number of their FDA and NCI colleagues who engaged with our LSC Members in a rich dialogue on data sharing and research innovation. The session included presentations by Dr. Oliver Sartor of Tulane University, and Dr. Howard Scher and Dr. Michael Morris of Memorial Sloan Kettering Cancer Center reviewing research derived from Project Data Sphere data, including the Prostate Cancer DREAM Challenge and the introduction of future research proposed by these esteemed academicians in concert with the FDA.
The Project Data Sphere® initiative has set big goals for 2016 – among them is to reach 100,000 patient lives of data, up from 30,000 patient lives today. We are working to close this gap through recommitments from existing data providers, pledges from new data sources and, in particular, by supporting de-identification of datasets from NCTN groups.

There is much to be proud of so far in 2016.
  • In February, we welcomed the first two blood cancer data sets to the platform, jointly uploaded by Millennium Pharmaceuticals Inc. and Janssen.
  • A new formal agreement from The Alliance for Clinical Trials in Oncology will provide data from all new Alliance studies to the Project Data Sphere platform.
  • Cross-industry working groups are forming now to explore inclusion of more types of data, additional applications for data from the platform, and expanded use by researchers.
  • The Project Data Sphere Board of Directors voted to include active arm data in the platform – we are working with both the National Cancer Institute (NCI) and industry data providers now to enable addition of new data types.
  • The PDS initiative was profiled in Cancer Discovery; subscribers may click here to read the article. Dr. Stephen Friend explained some of its uses and early successes from the current data.
New Data
  • Millennium Pharmaceuticals Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited) became the 13th Project Data Sphere data provider, uploading two data sets studying multiple myeloma in 674 patients (this was completed in conjunction with the Janssen Pharmaceutical Companies of Johnson & Johnson). These trials are the first blood cancer studies in the Project Data Sphere platform.
  • Ongoing discussions between Project Data Sphere leadership and the National Cancer Institute are rapidly advancing the plan to include data from trials sponsored by the National Clinical Trials Network in the Project Data Sphere platform.
  • The Project Data Sphere website was redesigned by CEO Roundtable Member SAS to enhance usability, particularly on mobile devices, and to further integrate the Community functionality. Additional major enhancements are currently in development, including the capability to support additional types of data, including experimental arm data.

CEO Roundtable on Cancer-China

NGO Registration
The CEO Roundtable on Cancer-China was formally registered on December 9, 2015, in China (Shanghai-Pudong), as the first NGO of its kind, opening new and promising vistas to the health of China.
CEO Cancer Gold Standard-China
The third CEO Cancer Gold Standard-China Task Force meeting was hosted on December 18, 2015, in the Yurt of Shanghai United Family Hospital in Changning District, Shanghai. As of January 1, the Task Force welcomed two Co-chairs, 20 Members and four Senior Advisors.

In late December 2015, China CDC announced it will become a Gold Standard accredited employer in China. This is a powerful endorsement of the CEO Roundtable’s health-advancing Gold Standard program.


Boehringer Ingelheim’s Gold Standard Journey
No progress is better reflected than by Gold Standard-China’s third accredited employer, Boehringer Ingelheim. By participating in the Gold Standard, BI is demonstrating its commitment not only to the health and well-being of its own employees but also to that of cancer patients and their families across China.

In March, our CEO Roundtable -China was honored to participate in celebrating the launch of BI’s 2016 China Be Healthy Program and to present the Gold Standard to BI's Health Ambassadors across the country.

On April 12, the CEO Roundtable-China shared BI's new message at the Huangpu CDC conference and celebrated with Huangpu CDC leadership about BI's achievements. Lily ZHOU, BI's Be Healthy leader, joined this event and presented BI's success story.
CEO Salon
On April 28, Dr. Murphy cohosted the CEO Salon with Mr. FAN Yaquan, Executive Vice President, Shanghai Pudong Association of Enterprises with Foreign Investment. C-suite leaders from 13 companies of various industries participated. Mr. SUN Yongqiang, Vice Chairman of China (Shanghai) Pilot Free Trade Zone and Vice Commissioner of Shanghai Pudong Commerce Commission, was the keynote speaker at the CEO Salon and encouraged more companies headquartered in Pudong to pursue Gold Standard accreditation in China.

An MOU Signing Ceremony with Shanghai Municipal Center for Disease Control and Prevention 
Professor WU Fan, Director General of SHCDC and Dr. Martin J. Murphy, chief executive officer of the CEO Roundtable on Cancer, signed a Memorandum of Understanding (MOU) of bilateral cooperation on April 27, 2016. Leaders of the CEO Roundtable-China, Vice Directors General, and department chiefs from SHCDC attended the ceremony at the SHCDC.
The two health-promoting organizations are committed to this MOU to enhance cooperation on health promotion, research cooperation and workplace wellness promotion.
 
“The CEO Roundtable’s focus on cancer prevention and research innovation provides powerful impetus for our bold and venturesome mission on behalf of the cancer patients to whom we are all dedicated. This MOU with Prof. WU Fan of Shanghai CDC marks a milestone in our common mission. We are proud and honored to join our SHCDC to help build a healthier municipality of Shanghai, for the benefit of all her people,” Dr. Murphy said.
 
Prof. WU Fan praised this MOU as a new starting point, for it paves the way for deeper and closer cooperation in the future. “With the CEO Roundtable’s many successful examples both in the U.S. and China, we hope we can work together in partnership to achieve more social benefits, and improve the health and quality of life of the general public.”
 
The MOU will strengthen health promotion media resources to be shared with the CEO Roundtable. For example, the CEO Roundtable-China will partner with SHCDC on a subway health promotion program that will spread health messages to 10+ million commuters in Shanghai. SHCDC. Committed to chronic disease prevention, SHCDC will work with the CEO Roundtable to promote the CEO Cancer Gold Standard workplace wellness programs in China. The MOU agreement will be valid for five years.

Audience with H.E. Dr. SHEN Xiaoming
On both January 21 and April 28,  H.E. Dr. SHEN Xiaoming, Party Secretary of Shanghai Pudong New Area and President, China (Shanghai) Free-Trade Zone, warmly received Dr. Murphy and the CEO Roundtable-China team. Dr. SHEN listened to a work report from the CEO Roundtable and praised its work in China and around the world. Dr. SHEN also encouraged the CEO Roundtable to make more contributions to China’s health by promoting the CEO Cancer Gold Standard to more employers in China and by enhancing research through introducing the pioneering, data sharing Project Data Sphere platform.


 
Founder



President George H. W. Bush
Forty-First President of the United States




Board of Directors

Robert A. Bradway
Chairman

Christopher A. Viehbacher
Immediate Past Chairman

Martin J. Murphy, DMedSc, PhD, FASCO
Chief Executive Officer

Robert A. Ingram
Past Chairman and Co-Founder

Mimi Hancock, PhD
Board Member

 
 
Mission
The CEO Roundtable on Cancer is committed to making continual progress toward the elimination of cancer as a personal disease and public health problem through initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to treatment, and hasten the discovery of effective therapies.

 
Connect
Visit the CEO Roundtable on Cancer website for a list of  Members, and to learn more about the CEO Cancer Gold Standard, the Life Sciences Consortium and the Project Data Sphere® initiative. 




























































































































































































































































































































































































































































































































































 
Copyright © 2016, CEO Roundtable on Cancer, All rights reserved.


Our mailing address is:
100 SAS Campus Drive, Cary, NC 27513

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list